3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Not yet recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Conditions
Carcinoma, Non-Small-Cell Lung
42
Lung Neoplasms
18
Melanoma
14
Carcinoma, Hepatocellular
14
Neoplasm Metastasis
13
Esophageal Neoplasms
11
Squamous Cell Carcinoma of Head and Neck
9
Breast Neoplasms
8
Head and Neck Neoplasms
6
Esophageal Squamous Cell Carcinoma
6
Rectal Neoplasms
5
Colorectal Neoplasms
5
Stomach Neoplasms
4
Recurrence
4
Neoplasms
4
Carcinoma, Renal Cell
4
Brain Neoplasms
4
Uterine Cervical Neoplasms
3
Triple Negative Breast Neoplasms
3
Small Cell Lung Carcinoma
3
Sarcoma
3
Precursor Cell Lymphoblastic Leukemia-Lymphoma
3
Pancreatic Neoplasms
3
Multiple Myeloma
3
Cholangiocarcinoma
3
Carcinoma, Transitional Cell
3
Radiation Pneumonitis
2
Pathologic Complete Response
2
Parkinson Disease 4, Autosomal Dominant Lewy Body
2
Oropharyngeal Neoplasms
2
Interventions
pembrolizumab
4
Nivolumab
3
toripalimab
2
sintilimab
2
Neoadjuvant Therapy
2
Celecoxib
2
tislelizumab
1
spartalizumab
1
relatlimab
1
regorafenib
1
fludarabine phosphate
1
fludarabine
1
durvalumab
1
denileukin diftitox
1
danvatirsen
1
camrelizumab
1
avelumab
1
atezolizumab
1
XELOX
1
Taxes
1
Surgical Procedures, Operative
1
Radiation Dose Hypofractionation
1
Paclitaxel
1
Megestrol Acetate
1
Medroxyprogesterone Acetate
1
Ipilimumab
1
Induction Chemotherapy
1
Immunotherapy
1
Immunoglobulin G
1
Immune Checkpoint Inhibitors
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
OTHER
×
Turcot syndrome
×
Immunotherapy
×
Clear all
NCT07259473
2026-01-07
Pre-CATALIS
Shanghai Zhongshan Hospital
Phase 2
Not yet recruiting
15 enrolled